BTK adenovirus

The Bruton''s tyrosine kinase (BTK) gene encodes a key non-receptor tyrosine kinase that plays a critical role in B-cell development, differentiation, and signaling. As a key component of the B-cell receptor (BCR) signaling pathway, BTK is essential for the maturation and survival of B lymphocytes. Mutations or dysregulation of the BTK gene can lead to severe immunodeficiencies such as X-linked agammaglobulinemia (XLA), which is characterized by the absence of mature B cells and impaired antibody production. In addition to its role in immunity, BTK has been implicated in the pathogenesis of certain B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), making it an attractive therapeutic target.

BTK adenovirus is a recombinant adenoviral vector designed to deliver the BTK gene or its modified variants to target cells for research or therapeutic applications. Adenoviruses are widely used in gene therapy due to their high transduction efficiency, broad tropism, and ability to infect both dividing and non-dividing cells. The BTK adenovirus can be used to study the function of BTK in vitro or in vivo by overexpressing BTK in specific cell types, such as B cells or cancer cells. In addition, it has the potential to be used in gene therapy approaches to correct BTK defects in diseases such as XLA. Researchers can also use the BTK adenovirus to study the downstream effects of BTK signaling or develop new strategies to target BTK in malignancies.